Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Showcasing Immune-Preservation and High Disease Control

Alpha Tau announced the submission of the first module of its pre-market approval (PMA) application FDA

- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones - JERUSALEM, December 18 th , 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CEO Uzi Sofer and CFO Raphi Levy   will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Th

- First patient in the world treated with Alpha DaRT ®  in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - Jerusalem, December 9, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW)